Evidence map›Paper›PMID 34665803›Full record

ArticlePLoS neglected tropical diseases2021

High SARS-CoV-2 seroprevalence in persons experiencing homelessness and shelter workers from a day-shelter in São Paulo, Brazil.

Anahi Chechia do Couto, Louise Bach Kmetiuk, Ruana Renostro Delai, Ana Pérola Drulla Brandão, Cairo Oliveira Monteiro, Luciana Helena Antoniassi da Silva, Camila Soares, Alexandre Campos Banari, Renato van Wilpe Bach, Christina Pettan-Brewer and 5 more

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Factors associated with the presence of anti-Frontiers in public health · 2025
    Article
  7. Article
  8. Article
  9. Serosurvey ofFrontiers in public health · 2023
    Article
  10. One health approach on serosurvey of anti-One health (Amsterdam, Netherlands) · 2022
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Anahi Chechia do CoutoGraduate College of Cellular and Molecular Biology, Federal University of Paraná (UFPR), Curitiba, Paraná, Brazil.ORCID 0000-0002-8113-3993
Louise Bach KmetiukGraduate College of Cellular and Molecular Biology, Federal University of Paraná (UFPR), Curitiba, Paraná, Brazil.ORCID 0000-0001-6579-1278
Ruana Renostro DelaiGraduate College of Cellular and Molecular Biology, Federal University of Paraná (UFPR), Curitiba, Paraná, Brazil.ORCID 0000-0003-4874-8336
Ana Pérola Drulla BrandãoDepartment of Preventive Medicine, University of São Paulo Medical School (FMUSP), São Paulo, São Paulo, Brazil.
Cairo Oliveira MonteiroDepartment of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Luciana Helena Antoniassi da SilvaDepartment of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Camila SoaresDepartment of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.ORCID 0000-0002-2161-7179
Alexandre Campos BanariDepartment of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Renato van Wilpe BachDepartment of Medicine, State University of Ponta Grossa, Ponta Grossa, Paraná, Brazil.ORCID 0000-0001-7173-1271
Christina Pettan-BrewerDepartment of Comparative Medicine, University of Washington, Seattle, Washington, United States of America.ORCID 0000-0002-5438-3890
Andrea Pires Dos SantosDepartment of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, West Lafayette, Indiana, United States of America.
Ana Marcia Sá GuimarãesDepartment of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Danielle Bruna Leal OliveiraDepartment of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Edison Luiz DurigonDepartment of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Alexander Welker BiondoGraduate College of Cellular and Molecular Biology, Federal University of Paraná (UFPR), Curitiba, Paraná, Brazil.ORCID 0000-0002-4182-5821
Universidade de São Paulo · BRUniversidade Federal do Paraná · BRPurdue University West Lafayette · USUniversidade Estadual de Ponta Grossa · BRUniversity of Washington · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Brazil presents one of the highest COVID-19 death tolls in the world. The initial SARS-CoV-2 epicenter was São Paulo city. As of 2019, the homeless population of São Paulo city was estimated at 24,344 individuals, the largest national homeless population. The present study aimed to concomitantly assess the molecular and serological prevalence and associated risk factors of SARS-CoV-2 infection in a homeless population and related shelter workers from a day-shelter. Serum samples, nasopharyngeal and oropharyngeal swabs of persons who are homeless and shelter workers collected from August 25th to 27th, 2020 were tested for the presence of anti-SARS-CoV-2 IgM and IgG antibodies by ELISA and SARS-CoV-2 RNA by RT-qPCR, respectively. All swab samples tested negative by RT-qPCR. Seropositivity of IgM and IgG was 5/203 (2.5%) and 111/203 (54.7%) in persons who are homeless, and 5/87 (5.7%) and 41/87 (47.1%) in shelter workers, respectively, with no statistical differences between groups. The high seroprevalence found herein indicates early environmental and urban spreading of SARS-CoV-2, associated with sociodemographic and economic vulnerability.

Indexed as

Ill-Housed PersonsAdolescentAdultAgedAged, 80 and overAntibodies, ViralBrazilCOVID-19Cross-Sectional StudiesFemaleHumansImmunoglobulin GImmunoglobulin MMaleMiddle AgedSARS-CoV-2Antibodies, ViralImmunoglobulin GImmunoglobulin M

Identifiers

PMID34665803
PMCPMC8525740
OpenAlexW3207908613

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.